Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEOs have to file when they are selling there shares.... which they did 3 months prior to the run. Nice try though
We take off without you????
Good day today my friend $$$$$$$)
https://finance.yahoo.com/m/046202af-6de4-3788-acfe-cbe90d929b81/why-royal-caribbean-.html
Here is ACTUAL DD $$$$$$$$$$$$$$$$$$$$$$
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter. You can find articles about an individual hedge fund's trades on numerous financial news websites. However, in this article we will take a look at their collective moves over the last 5 years and analyze what the smart money thinks of Gilead Sciences, Inc. (NASDAQ:GILD) based on that data and determine whether they were really smart about the stock.
Is Gilead Sciences, Inc. (NASDAQ:GILD) a buy here? The smart money was in a pessimistic mood. The number of bullish hedge fund bets dropped by 8 in recent months. Gilead Sciences, Inc. (NASDAQ:GILD) was in 68 hedge funds' portfolios at the end of June. The all time high for this statistics is 93. Our calculations also showed that GILD isn't among the 30 most popular stocks among hedge funds (click for Q2 rankings and see the video for a quick look at the top 5 stocks). Video: Watch our video about the top 5 most popular hedge fund stocks.
Why do we pay any attention at all to hedge fund sentiment? Our research has shown that a select group of hedge fund holdings outperformed the S&P 500 ETFs by 56 percentage points since March 2017 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that'll significantly underperform the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 34% through August 17th. That's why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.
Ric Dillon Diamond Hill Capital
Ric Dillon Diamond Hill Capital
Ric Dillon of Diamond Hill Capital
At Insider Monkey we scour multiple sources to uncover the next great investment idea. For example, legal marijuana is one of the fastest growing industries right now, so we are checking out ideas like this under-the-radar stock to identify the next tenbagger. Currently, investors are pessimistic about commercial real estate investments. So, we are checking out this contrarian play to diversify our market exposure. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. If you want to find out the best healthcare stock to buy right now, you can watch our latest hedge fund manager interview here. Now let's review the fresh hedge fund action regarding Gilead Sciences, Inc. (NASDAQ:GILD).
How are hedge funds trading Gilead Sciences, Inc. (NASDAQ:GILD)?
At the end of June, a total of 68 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -11% from the previous quarter. Below, you can check out the change in hedge fund sentiment towards GILD over the last 20 quarters. So, let's review which hedge funds were among the top holders of the stock and which hedge funds were making big moves.
The largest stake in Gilead Sciences, Inc. (NASDAQ:GILD) was held by Renaissance Technologies, which reported holding $684.9 million worth of stock at the end of September. It was followed by AQR Capital Management with a $352.7 million position. Other investors bullish on the company included Citadel Investment Group, Diamond Hill Capital, and Arrowstreet Capital. In terms of the portfolio weights assigned to each position Healthcare Value Capital allocated the biggest weight to Gilead Sciences, Inc. (NASDAQ:GILD), around 9.82% of its 13F portfolio. Unio Capital is also relatively very bullish on the stock, dishing out 4.13 percent of its 13F equity portfolio to GILD.
Judging by the fact that Gilead Sciences, Inc. (NASDAQ:GILD) has faced bearish sentiment from hedge fund managers, it's easy to see that there were a few money managers that elected to cut their entire stakes in the second quarter. At the top of the heap, Phill Gross and Robert Atchinson's Adage Capital Management dumped the largest stake of all the hedgies followed by Insider Monkey, comprising about $83.2 million in stock, and Fang Zheng's Keywise Capital Management was right behind this move, as the fund cut about $61.6 million worth. These moves are interesting, as aggregate hedge fund interest dropped by 8 funds in the second quarter.
Let's check out hedge fund activity in other stocks similar to Gilead Sciences, Inc. (NASDAQ:GILD). These stocks are Royal Bank of Canada (NYSE:RY), United Parcel Service, Inc. (NYSE:UPS), Anheuser-Busch InBev SA/NV (NYSE:BUD), HSBC Holdings plc (NYSE:HSBC), JD.Com Inc (NASDAQ:JD), Raytheon Technologies Corp (NYSE:RTX), and 3M Company (NYSE:MMM). This group of stocks' market caps are closest to GILD's market cap.
[table] Ticker, No of HFs with positions, Total Value of HF Positions (x1000), Change in HF Position RY,16,237643,0 UPS,37,781926,-11 BUD,17,860874,0 HSBC,10,384518,-4 JD,87,11211241,-3 RTX,59,2951712,-3 MMM,42,1038241,-2 Average,38.3,2495165,-3.3 [/table]
View table here if you experience formatting issues.
As you can see these stocks had an average of 38.3 hedge funds with bullish positions and the average amount invested in these stocks was $2495 million. That figure was $2286 million in GILD's case. JD.Com Inc (NASDAQ:JD) is the most popular stock in this table. On the other hand HSBC Holdings plc (NYSE:HSBC) is the least popular one with only 10 bullish hedge fund positions. Gilead Sciences, Inc. (NASDAQ:GILD) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for GILD is 56.6. Stocks with higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score. This is a slightly positive signal but we'd rather spend our time researching stocks that hedge funds are piling on. Our calculations showed that top 10 most popular stocks among hedge funds returned 41.4% in 2019 and outperformed the S&P 500 ETF (SPY) by 10.1 percentage points. These stocks gained 28.2% in 2020 through August 24th but beat the market by 20.6 percentage points. Unfortunately GILD wasn't nearly as popular as these 10 stocks and hedge funds that were betting on GILD were disappointed as the stock returned -14.1% during the same time period and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 10 most popular stocks among hedge funds as many of these stocks already outperformed the market so far this year.
Shorty going to get caught with his pants down VERY SOON!!!!!
Break 508 and we definitely have a next leg up$$$$$
Wedbush analyst Dan Ives says Apple has a 'once in a decade' opportunity to capitalize on iPhone upgrades as 5G networks roll out around the world, and argues a bull case of $700 per share for the world's biggest tech company.
MARTIN BACCARDAXUPDATED:AUG 26, 2020 7:34 AM EDTORIGINAL:AUG 26, 2020
Apple Inc. (AAPL) - Get Report shares moved higher in pre-market trading Wednesday after analysts at Wedbush Securities issued yet another price target boost for the tech giant, setting out a bull case that could lift it to $700 per share.
Wedbush analyst Dan Ives, a consistent and long-term Apple bull, lifted his Apple price target to $600 per share Wednesday, the highest on Wall Street, amid what he calls a 'once in a decade' opportunity for the tech giant to take advantage of iPhone upgrades ahead of the advance of 5G infrastructure rollouts and the launch of the iPhone 12.
Ives says around 350 million of the 950 million iPhones in circulation could be upgraded over the next 12 to 18 months, with around 20% of those coming from China, arguably Apple's most important market.
"China remains a key ingredient in Apple’s recipe for success (and) to this point we are seeing considerable strength from the China region over the last few months with positive trends heading into the fall, an impressive trajectory we expect to continue heading into the next 6 to 9 months," Ives said. "Despite the noise, based on our recent discussions with contacts within the Beltway we strongly believe the WeChat ban will not negatively impact or disrupt Apple's iPhone ecosystem within the key China market."
Apple shares were marked 1.13% higher in pre-market trading Wednesday to indicate an opening bell price of $502.70 each, a move that would extend the stock's three-month gain to around 57.6% and value the Cupertino, California-based company at around $2.15 trillion.
Coronavirus Market Update: Sign up for TheStreet's Coronavirus Market Update newsletter and get the latest market headlines delivered to your inbox daily.
Ives says his 'bull case' for Apple includes a price target of $700 per share, a value he sees as realistic given that the iPhone 12 "represents the most significant product cycle for Cook & Co. since iPhone 6 in 2014 and will be another defining chapter in the Apple growth story looking ahead despite a softer consumer spending environment in our opinion."
"We still believe many on the Street are underestimating the massive pent-up demand around this supercycle for Apple, which remains the opportunity for the bulls heading into 2021 as this monetization engine heads into its next gear," Ives said.
Apple now accounts for around 7% of the S&P 500's total market capitalization, and is worth more than the combined value of the benchmark's 200 smallest companies, according to Reuters data and reporting.
The stock's impact on the Dow Jones Industrial Average, however, is set to wane next week after the group announced a four-for-one stock split that will take effect on August 31.
Wednesday's pre-market gain, for examples, adds around 25 points to the Dow, based on its current share price in pre-market trading. A similar gain at $125 per share -- when the split becomes effective on August 31 -- would add only 5 points to the price-weighted average.
Apple said earnings for the three months ending in June, the group's fiscal third quarter, rose 25.9% from the same period last year to $2.58 per share, well ahead of the $2.05 per share Street consensus forecast. Group revenues rose 13.4% to a Street-beating $59.7 billion, Apple said, with gains in every geographical region and across all product line.
iPhone revenues rose 2% from last year to a forecast-beating $26.4 billion, despite the COVID-19 headwinds, thanks in part to a solid debut for the $399 iPhone SE, which was launched earlier this year. iPad and iMac sales, meanwhile, rose 22% and 31% respectively as work-from-home shifts powered computer purchases. Services revenues were pegged at $13.2 billion, just shy of Apple's recent record and up 15% from last year.
Apple declined to offer a near-term profit forecast, "given the uncertainty around the world' and the ongoing COVID-19 impact, but noted that it expects to see continued gains for the iPhone, despite likely delays of "a few weeks" for its iPhone 12 launch in September.
Martin Baccardax
BY MARTIN BACCARDAX
Jim Cramer: Honeywell Has 'Certain Things Going for It'
hotels travel sh
PERSONAL FINANCE
Which Hotel Chains Rate the Best for Health and Flexibility Policies?
BY NERDWALLET
Jim Cramer Is Watching Urban Outfitters and e.l.f Beauty's Earnings
INVESTING
Urban Outfitters Soars Post Earnings on Analysts' Upgrades
BY M. COREY GOLDMAN
U.S. Markets Rally Likely to Continue Beyond Tuesday - NYSE Trader
INVESTING
Dow Futures Sputter Ahead of Powell Speech; Hurricane Laura Bears Down on Texas and Louisiana Coast
BY MARTIN BACCARDAX
PERSONAL FINANCE
Will Student Loans Cover Living Expenses If Your College Is Online?
BY NERDWALLET
INVESTING
McDonald’s Probing Additional Internal Cover-Ups by Former CEO
BY M. COREY GOLDMAN
MARKETS
Salesforce, Palantir, Hurricane Laura - 5 Things You Must Know Wednesday
BY JOSEPH WOELFEL
INVESTING
Salesforce Surges to Record High After Q2 Earnings Blowout
BY MARTIN BACCARDAX
LATEST NEWS
Hurricane Laura, 'Rapidly Accelerating' Into Category 4 Storm, Heads for Texas and Louisiana
BY MARTIN BACCARDAX
SEE MORE
TheStreet
Terms Of Use
Privacy Policy
Advertise
Reprints
Customer Service
Data
Topic Archive
Subscriptions
© 2020 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.
Coming from the same country that gave the United States COVID 19....
come on shorty!!!!! Give us REAL DD
500 printing again $$$$$$$
Back to 500 we go $$$$$$
I appreciate these shares under 500. Been patiently waiting. GLTA. Looking forward to sharing new DD in the future. Best of trades to NEW longs as well
I’ll be loading tomorrow. Trying to see how low it goes before the split. GLTA, see some of you tomorrow
Looking forward to buying shares here Friday before the split. GLTA here who are longs and looking forward to meeting new ihub member longs !!!!!!! See some of you Friday
RISK vs REWARD!
I’ve watched it run Twice now. 3s are charm$$$$
GLTA wish I had a crystal ball to answer your concerns
16s printing $$$$$$$
Positive news yesterday equal positive results for airlines today
WH press conference at 6. Possible vaccine???? Stay tuned. Potentially big news. Will MRNA be the one????
https://www.fool.com/investing/2020/08/23/better-coronavirus-stock-curevac-vs-moderna/
Very close MRNA longs!!!!!
emergency use authorization by US regulators for its drug remdesivir to include patients hospitalized with moderate COVID-19, despite recent mixed trial results, the company’s top research executive told Reuters on Friday.
Data published by Gilead (GILD) on Friday showed that a 5-day course of intravenous remdesivir modestly helped less severely ill COVID-19 patients, but a 10-day course did not show a benefit.
Back in May, the US Food and Drug Administration (FDA) approved sales of remdesivir on an emergency basis for patients hospitalized with severe COVID-19, the disease caused by the new coronavirus, after trial data showed that the antiviral drug helped shorten their hospital recovery time.
Scroll to continue with contentAd
249 Hotel Brands. Endless Experiences
Diana Brainard, head of clinical research at Gilead, also told Reuters that the company’s formal FDA application for the drug, submitted earlier this month, seeks approval for use in all hospitalized patients with COVID-19.
The 600-patient analysis, published by the Journal of the American Medical Association, found that moderately ill patients treated with the antiviral drug for up to 5 days had significantly higher odds of improvement in certain areas, such as whether or not they needed supplemental oxygen, compared to patients given standard treatment.
Brainard said the clinical importance of the benefit for those patients was uncertain, due to continued questions about how best to measure patient outcomes other than survival.
Differing trial results for remdesivir raise “the question of whether the discrepancies are artifacts of study design choices, including patient populations, or whether the drug is less efficacious than hoped,” according to a JAMA editorial accompanying the study.
The study in moderately ill COVID-19 patients demonstrated that 11 days after starting treatment, 65% of the 10-day remdesivir patients, 70% of the 5-day patients and 60% of the standard care patients had left the hospital.
Side effects seen more frequently in the remdesivir groups included nausea, low blood potassium levels, and headache.
The JAMA editorial said important questions remain regarding the efficacy of remdesivir, including which patients are most likely to benefit from the drug, the optimal duration of therapy, the drug’s impact on clinical outcomes, and its relative effect if combined with generic steroid treatments.
Shares in Gilead have advanced about 2.3% year-to-date with the $78.31 average price target indicating another 18% upside potential in the shares in the coming 12 months.
Truist Financial analyst Robyn Karnauskas last week lowered the stock’s price target to $67 from $74 and reiterated a Hold rating, saying that while there is some visibility around the commercialization from remdesivir in COVID-19, there is still "commercial risk" for the program
Thank you for your professional opinion.... Absolutely garbage. That it all Mr. Shorty
Mittleman Brothers recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Mittleman Global Value Equity Fund – Class P advanced 13.0% net of fees (AUD) in the second quarter of 2020, versus a gain of 6.0% in the MSCI ACW Index. You should check out Mittleman Brothers' top 5 stock picks for investors to buy right now, which could be the biggest winners of the stock market crash.
In the said letter, Mittleman Brothers' highlighted a few stocks and Carnival Corp (NYSE:CCL) is one of them. Carnival Corp (NYSE:CCL) is a cruise company. Year-to-date, Carnival Corp (NYSE:CCL) stock lost 71.4% and on August 20th it had a closing price of $14.54. Here is what Mittleman Brothers' said:
"The third best performer in Q2 was Carnival Corp. (CCL). The position was established at around $8.33 per share with roughly half sold at prices between $14 and $25. The current downturn in the cruise business is unprecedented, but CCL is well equipped to survive it, with access to capital through asset sales or mortgages. Add to this a very loyal and growing hoard of customers that really, really loves the cruise experience, despite the increasingly obvious drawbacks. Actual FCF is much greater than it appears as regular spend on new ships are not just replacements but are generally growth initiatives. Running with limited capital spend the FCF would be immense, around $2B per year on $5B in EBITDA (normalised). MIM puts fair value for CCL close to $40 at 9.4x EBITDA and 14x FCF."
Top 10 Countries With The Highest Immigration to US
Top 10 Countries With The Highest Immigration to US
Vlad G/Shutterstock.com
Last month, we published an article revealing that Silver Ring Value Partners LP is bullish about Carnival Corp (NYSE:CCL) stock. The investment firm believes that the company would emerge stronger from the coronavirus crisis.
In Q1 2020, the number of bullish hedge fund positions on Carnival Corp (NYSE:CCL) stock decreased by about 9% from the previous quarter (see the chart here), so a number of other hedge fund managers don't seem to agree with Carnival's upside potential. Our calculations showed that Carnival Corp (NYSE:CCL) isn't ranked among the 30 most popular stocks among hedge funds.
The top 10 stocks among hedge funds returned 185% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 109 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds' poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.
https://seekingalpha.com/article/4369775-covidminus-19-real-results-are-long-way-away
Must read for all MRNA longs !!!!!!
$$$$$$$$$$$
Monday should b interesting!!!!! Expecting news anytime $$$$$$ PLYN $$$$$$
$$$$$$$$$$$$$$$$